325 related articles for article (PubMed ID: 26702990)
21. Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Med Oncol; 2016 Dec; 33(12):137. PubMed ID: 27815805
[TBL] [Abstract][Full Text] [Related]
22. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
[TBL] [Abstract][Full Text] [Related]
23. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer.
Liu YM; Shiau CY; Lee ML; Huang PI; Hsieh CM; Chen PH; Lin YH; Wang LW; Yen SH
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1113-23. PubMed ID: 17197126
[TBL] [Abstract][Full Text] [Related]
24. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
25. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
[TBL] [Abstract][Full Text] [Related]
26. Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation.
Rose B; Mitra D; Hong TS; Jee KW; Niemierko A; Drapek LN; Blaszkowsky LS; Allen JN; Murphy JE; Clark JW; Ryan DP; Wo JY
Pract Radiat Oncol; 2017; 7(5):e291-e297. PubMed ID: 28462895
[TBL] [Abstract][Full Text] [Related]
27. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
28. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
29. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies.
Brixey CJ; Roeske JC; Lujan AE; Yamada SD; Rotmensch J; Mundt AJ
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1388-96. PubMed ID: 12459361
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow sparing in prostate cancer patients treated with Post-operative pelvic nodal radiotherapy - A proton versus photon comparison.
De Ornelas M; Iorio GC; Bossart E; Ricardi U; Seldon C; Dal Pra A; Butkus M
Phys Med; 2023 Aug; 112():102644. PubMed ID: 37487297
[TBL] [Abstract][Full Text] [Related]
31. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
[TBL] [Abstract][Full Text] [Related]
32. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
33. Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation.
Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Trino E; Cassoni P; Arena V; Baccega M; Racca P; Faletti R; Rondi N; Morino M; Ricardi U
Cancer Invest; 2018; 36(5):279-288. PubMed ID: 29953269
[TBL] [Abstract][Full Text] [Related]
34. [Pelvic irradiation and hematopoietic toxicity: A review of the literature].
Kuntz L; Noel G
Cancer Radiother; 2021 Feb; 25(1):77-91. PubMed ID: 33358082
[TBL] [Abstract][Full Text] [Related]
35. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
36. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
37. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
[TBL] [Abstract][Full Text] [Related]
38. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
39. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.
Wang D; Yin Y; Zhou Q; Li Z; Ma X; Yin Y; Li B; Bai T; Li D; Zhu J
Med Phys; 2022 Jan; 49(1):756-767. PubMed ID: 34800297
[TBL] [Abstract][Full Text] [Related]
40. Hematologic Toxicity of Conformal Radiotherapy and Intensity Modulated Radiotherapy in Prostate and Bladder Cancer Patients.
Miszczyk M; Majewski W
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2803-2806. PubMed ID: 30360609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
